285 related articles for article (PubMed ID: 36371025)
1. Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response.
Khan P; Fatima M; Khan MA; Batra SK; Nasser MW
Semin Cancer Biol; 2022 Dec; 87():117-126. PubMed ID: 36371025
[TBL] [Abstract][Full Text] [Related]
2. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer.
Tian Y; Li Q; Yang Z; Zhang S; Xu J; Wang Z; Bai H; Duan J; Zheng B; Li W; Cui Y; Wang X; Wan R; Fei K; Zhong J; Gao S; He J; Gay CM; Zhang J; Wang J; Tang F
Signal Transduct Target Ther; 2022 Oct; 7(1):346. PubMed ID: 36195615
[TBL] [Abstract][Full Text] [Related]
3. Killing SCLC: insights into how to target a shapeshifting tumor.
Sutherland KD; Ireland AS; Oliver TG
Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
[TBL] [Abstract][Full Text] [Related]
4. The role of chemokine receptor CXCR4 in lung cancer.
Gangadhar T; Nandi S; Salgia R
Cancer Biol Ther; 2010 Mar; 9(6):409-16. PubMed ID: 20147779
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.
Li X; Li Y; Zhao Z; Miao N; Liu G; Deng L; Wei S; Hou J
Cancer Med; 2023 Feb; 12(4):4864-4881. PubMed ID: 35957613
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
Khan P; Siddiqui JA; Kshirsagar PG; Venkata RC; Maurya SK; Mirzapoiazova T; Perumal N; Chaudhary S; Kanchan RK; Fatima M; Khan MA; Rehman AU; Lakshmanan I; Mahapatra S; Talmon GA; Kulkarni P; Ganti AK; Jain M; Salgia R; Batra SK; Nasser MW
Mol Cancer; 2023 Jan; 22(1):1. PubMed ID: 36597126
[TBL] [Abstract][Full Text] [Related]
7. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.
Vilgelm AE; Richmond A
Front Immunol; 2019; 10():333. PubMed ID: 30873179
[TBL] [Abstract][Full Text] [Related]
8. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
9. Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities.
Desai P; Takahashi N; Kumar R; Nichols S; Malin J; Hunt A; Schultz C; Cao Y; Tillo D; Nousome D; Chauhan L; Sciuto L; Jordan K; Rajapakse V; Tandon M; Lissa D; Zhang Y; Kumar S; Pongor L; Singh A; Schroder B; Sharma AK; Chang T; Vilimas R; Pinkiert D; Graham C; Butcher D; Warner A; Sebastian R; Mahon M; Baker K; Cheng J; Berger A; Lake R; Abel M; Krishnamurthy M; Chrisafis G; Fitzgerald P; Nirula M; Goyal S; Atkinson D; Bateman NW; Abulez T; Nair G; Apolo A; Guha U; Karim B; El Meskini R; Ohler ZW; Jolly MK; Schaffer A; Ruppin E; Kleiner D; Miettinen M; Brown GT; Hewitt S; Conrads T; Thomas A
Cell Rep Med; 2024 Jun; 5(6):101610. PubMed ID: 38897168
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation.
Guo H; Li W; Guo Y; Chen N; Cui J
Chin Med J (Engl); 2024 Jan; 137(2):130-139. PubMed ID: 37660289
[TBL] [Abstract][Full Text] [Related]
13. Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance.
Jin Y; Chen Y; Qin Z; Hu L; Guo C; Ji H
Acta Biochim Biophys Sin (Shanghai); 2023 May; 55(6):948-955. PubMed ID: 37249335
[TBL] [Abstract][Full Text] [Related]
14. Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities.
Yang L; Zhang Z; Dong J; Zhang Y; Yang Z; Guo Y; Sun X; Li J; Xing P; Ying J; Zhou M
Pharmacol Res; 2023 Aug; 194():106844. PubMed ID: 37392900
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
Song Y; Sun Y; Sun T; Tang R
Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
[TBL] [Abstract][Full Text] [Related]
16. Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.
Pan Y; Hao Y; Han H; Chen T; Ding H; Labbe KE; Shum E; Guidry K; Hu H; Sherman F; Geng K; Stephens J; Chafitz A; Tang S; Huang HY; Peng C; Almonte C; Lopes JE; Losey HC; Winquist RJ; Velcheti V; Zhang H; Wong KK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36472839
[TBL] [Abstract][Full Text] [Related]
17. Genetically-engineered mouse models of small cell lung cancer: the next generation.
Oser MG; MacPherson D; Oliver TG; Sage J; Park KS
Oncogene; 2024 Feb; 43(7):457-469. PubMed ID: 38191672
[TBL] [Abstract][Full Text] [Related]
18. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer.
Pandey M; Mukhopadhyay A; Sharawat SK; Kumar S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188552. PubMed ID: 33892053
[TBL] [Abstract][Full Text] [Related]
19. Genomic and transcriptomic profiling of combined small-cell lung cancer through microdissection: unveiling the transformational pathway of mixed subtype.
Ma W; Zhou T; Song M; Liu J; Chen G; Zhan J; Ji L; Luo F; Gao X; Li P; Xia X; Huang Y; Zhang L
J Transl Med; 2024 Feb; 22(1):189. PubMed ID: 38383412
[TBL] [Abstract][Full Text] [Related]
20. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
